FAAH inhibitors in the limelight, but regrettably - Université Clermont Auvergne Accéder directement au contenu
Article Dans Une Revue International Journal of Clinical Pharmacology and Therapeutics Année : 2016

FAAH inhibitors in the limelight, but regrettably

Résumé

This short review focuses on the recent drug development of FAAH inhibitors, as recent serious adverse events have been reported in a phase I study with a compound of this class. The authors overview the potential interest in targeting FAAH inhibition, the current programs, and the available information on the recent dramatic events. 3 See refs. on Clinicaltrials.gov: NCT02134080,
Fichier principal
Vignette du fichier
intjclinpharmacol-54-498.pdf (325.88 Ko) Télécharger le fichier
Origine : Publication financée par une institution
Licence : CC BY - Paternité

Dates et versions

hal-04337687 , version 1 (12-12-2023)

Licence

Paternité

Identifiants

Citer

Christophe Mallet, Claude Dubray, Christian Dualé. FAAH inhibitors in the limelight, but regrettably. International Journal of Clinical Pharmacology and Therapeutics, 2016, 54 (07), pp.498 - 501. ⟨10.5414/cp202687⟩. ⟨hal-04337687⟩

Collections

PRES_CLERMONT ND
18 Consultations
12 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More